Custom Protein Generation

Drug Substance Manufacturing

Drug Product Fill & Finish

Development

Testing

Discovery

Antibody Drug Conjugates

Technologies & Platforms

WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai

2018/11/22

SHANGHAI, November 22, 2018 –WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that construction of a global innovation center has commenced in the district of Fengxian in Shanghai.

The new state-of-the-art biologics center will integrate biologics discovery, development, clinical and commercial manufacturing which will be built to meet global cGMP standards while implementing modular and flexible design. This will be one of the largest facilities of its kind with 1.6 million sq. ft. and will accommodate more than 3000 scientists.

“The commencement of this new biologics center will further expand WuXi Biologics’ unparalleled capacities and we are glad to witness its construction today. WuXi Biologics is committed to developing and manufacturing biologics more cost effectively as well as to providing a robust supply chain network for our global partners to benefit patients worldwide,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

Media Contact

WuXi Biologics

Jia Li
li_jia0102@wuxiapptec.com

BACK